Login

**media[1067807]**TAIPEI, May 22, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. announces that its abstract highlighting the differentiated binding profile and preclinical efficacy of TSY-310, a novel bispecific antibody-drug conjugate (ADC), has been selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 - June 2, 2026, in Chicago, Illinois.  TSY-310 simultaneously targets EGFR and ROR1, two receptors frequently co-expressed in prevalent solid tumors. By leveraging a unique bispecific modality, TSY-310 optimizes target engagement and intracellular delivery, facilitating a potent bystander effect to address the challenges of tumor heterogeneity.DetailsTitle:TSY-310, A Novel Bispecific EGFR x ROR1 ADC, Exhibits Potent Antitumor Activity in Heterogeneous Breast Tumors Through Enhanced Internalization and Bystander CytotoxicitySession: Developmental Therapeutics: Molecularly Targeted Agents and Tumor BiologyDate & Time: May 30, 2026, 1:30 pm - 4:30 pm CTAbstract Number: 3086Poster Number: 223Presenter: Dr. Kuo-Ming Yu, Ph.D., Director, CMC and ProductionHighlightsSuperior Selectivity: Bispecific binding, enhancing internalization specifically in tumor cells co-expressing EGFR and ROR1.Enhanced Payload Delivery: Evidence of efficient lysosomal trafficking and the subsequent release of the cytotoxic payload.Bystander Efficacy: Eradication of neighboring antigen-negative tumor cells, a critical factor in treating complex, heterogeneous tumor environments. 'Our participation at ASCO is an acknowledgement of the program's potential as a worthy contributor to the future oncology treatment landscape,' said Erick Co, President & CEO of Formosa Pharmaceuticals. 'We are eager to place TSY-310 in the toolbox of oncologists and patients who face the evolving challenges with traditional single-target therapies.'